Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by Stylesson Jul 02, 2015 3:08pm
25 Views
Post# 23887351

RE:RE:if the stock couldn't rally today

RE:RE:if the stock couldn't rally todaybut every healthcare stock did though haha

Only two i know that have not done well were the original healthcare cos (CPH and RX). They had their year back in 2013 early 2014.

Now, there's so many others that are taking attention away from these names that have high single drug risk and are not attractive anymore relative to the new emerging ones.

Look at CXR, CRH, NHC, TH, RVX, PHM, etc. These are all up huge. Their relative outperformance against CPH is a minimum of 100% ytd. as much as +300-400% at the high end.ha

CPH is a loser stock. Just look at it. Don't say post facts. Because all you have to do is look at the share price. Just look at it for a change Lieseeker.

Even at 11 bucks, this stock trades at ~25x eps. TOO EXPENSIVE FOR A HIGH RISK SINGLE DRUG WONDER WHO'S MARKET SHARE IS PEAKING WITH NO VIABLE AND IMMEDIATE GROWTH PLANS.


Bullboard Posts